In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary ...

The SOUL cardiovascular outcomes trial was a double-blinded, randomised trial that compared oral semaglutide to placebo as an ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

A new meta-analysis confirms that semaglutide drugs like Ozempic are not only effective for weight loss, but can also protect ...